1. ZHAW digitalcollection
  2. Life Sciences und Facility Management
  3. Publikationen
  4. Publikationen Life Sciences und Facility Management
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFischer, Thomas-
dc.contributor.authorGazzola, Silvia-
dc.contributor.authorRiedl, Rainer-
dc.date.accessioned2021-02-18T10:39:01Z-
dc.date.available2021-02-18T10:39:01Z-
dc.date.issued2019-06-10-
dc.identifier.issn1746-0441de_CH
dc.identifier.issn1746-045Xde_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/21748-
dc.description.abstractIntroduction: The development of drug candidates with a defined selectivity profile and a unique molecular structure is of fundamental interest for drug discovery. In contrast to the costly screening of large substance libraries, the targeted de novo design of a drug by using structural information of either the biological target and/or structure-activity relationship data of active modulators offers an efficient and intellectually appealing alternative. Areas covered: This review provides an overview on the different techniques of de novo drug design (ligand-based drug design, structure-based drug design, and fragment-based drug design) and highlights successful examples of this targeted approach toward selective modulators of therapeutically relevant targets. Expert opinion: De novo drug design has established itself as a very efficient method for the development of potent and selective modulators for a variety of different biological target classes. The ever-growing wealth of structural data on therapeutic targets will certainly further enhance the importance of de novo design for the drug discovery process in the future. However, a consistent use of the terminology of de novo drug design in the scientific literature should be sought.de_CH
dc.language.isoende_CH
dc.publisherTaylor & Francisde_CH
dc.relation.ispartofExpert Opinion on Drug Discoveryde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectDrug designde_CH
dc.subjectFragment-based drug designde_CH
dc.subjectLigand-based drug designde_CH
dc.subjectMedicinal chemistryde_CH
dc.subjectSelectivityde_CH
dc.subjectStructure-based drug designde_CH
dc.subjectDrug developmentde_CH
dc.subjectDrug discoveryde_CH
dc.subjectHumansde_CH
dc.subjectLigandsde_CH
dc.subjectStructure-activity relationshipde_CH
dc.subjectMolecular targeted therapyde_CH
dc.subject.ddc615: Pharmakologie und Therapeutikde_CH
dc.titleApproaching target selectivity by de novo drug designde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementLife Sciences und Facility Managementde_CH
zhaw.organisationalunitInstitut für Chemie und Biotechnologie (ICBT)de_CH
dc.identifier.doi10.1080/17460441.2019.1615435de_CH
dc.identifier.pmid31179763de_CH
zhaw.funding.euNode_CH
zhaw.issue8de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end803de_CH
zhaw.pages.start791de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume14de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.webfeedCC Drug Discoveryde_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen Life Sciences und Facility Management

Files in This Item:
There are no files associated with this item.
Show simple item record
Fischer, T., Gazzola, S., & Riedl, R. (2019). Approaching target selectivity by de novo drug design. Expert Opinion on Drug Discovery, 14(8), 791–803. https://doi.org/10.1080/17460441.2019.1615435
Fischer, T., Gazzola, S. and Riedl, R. (2019) ‘Approaching target selectivity by de novo drug design’, Expert Opinion on Drug Discovery, 14(8), pp. 791–803. Available at: https://doi.org/10.1080/17460441.2019.1615435.
T. Fischer, S. Gazzola, and R. Riedl, “Approaching target selectivity by de novo drug design,” Expert Opinion on Drug Discovery, vol. 14, no. 8, pp. 791–803, Jun. 2019, doi: 10.1080/17460441.2019.1615435.
FISCHER, Thomas, Silvia GAZZOLA und Rainer RIEDL, 2019. Approaching target selectivity by de novo drug design. Expert Opinion on Drug Discovery. 10 Juni 2019. Bd. 14, Nr. 8, S. 791–803. DOI 10.1080/17460441.2019.1615435
Fischer, Thomas, Silvia Gazzola, and Rainer Riedl. 2019. “Approaching Target Selectivity by de Novo Drug Design.” Expert Opinion on Drug Discovery 14 (8): 791–803. https://doi.org/10.1080/17460441.2019.1615435.
Fischer, Thomas, et al. “Approaching Target Selectivity by de Novo Drug Design.” Expert Opinion on Drug Discovery, vol. 14, no. 8, June 2019, pp. 791–803, https://doi.org/10.1080/17460441.2019.1615435.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.